ArticleFrontiers in medicine2026
Short-term outcomes of intravitreal faricimab on refractory neovascular age-related macular degeneration patients in China.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the real-world clinical outcomes of faricimab in patients receiving treatment for neovascular age-related macular degeneration (nAMD). Methods: This real-world prospective observational study included patients with refractory nAMD. In total, 37 patients were analyzed. All patients had previously undergone at least three consecutive intravitreal injections of other anti-vascular endothelial growth factor (anti-VEGF) agents. The primary outcomes were best-corrected visual acuity (BCVA) and anatomical outcomes on optical coherence tomography angiography (OCTA) at a four-month follow-up period. Results: The faricimab regimen resulted in significant improvements in both visual and anatomical parameters among patients with refractory nAMD. LogMAR BCVA decreased substantially from 0.82 ± 0.42 to 0.57 ± 0.32 ( Conclusion: Faricimab given as three monthly loading doses demonstrates significant short-term improvement in vision and anatomical outcomes, including rapid gains in BCVA and reductions in CST and retinal fluid. It appears effective and well-tolerated for refractory nAMD, particularly in reducing SRF and improving visual acuity, though its effect on IRF resolution was limited and not statistically significant. However, because the study design confounded drug switch with increased injection frequency, the independent contribution of faricimab itself cannot be determined. No adverse safety signals were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.